首頁 > 市場調查報告書 > 製藥

眼科藥物

視網膜藥物市場規模、佔有率、成長分析（依藥物類別、適應症、劑型、通路、地區）－2025-2032 年產業預測

市場調查報告書

商品編碼

1722223

視網膜藥物市場規模、佔有率、成長分析（依藥物類別、適應症、劑型、通路、地區）－2025-2032 年產業預測

Retinal Drugs Market Size, Share, and Growth Analysis, By Component (Anti-VEGF Agents, Gene & Cell Therapies), By Indication (Macular Degeneration, Diabetic Retinopathy), By Formulation, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年05月02日 | 出版商:

SkyQuest | 英文 186 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球視網膜藥物市場規模為 202 億美元，預計將從 2024 年的 218.6 億美元成長到 2032 年的 410.6 億美元，預測期內（2025-2032 年）的複合年成長率為 8.2%。

由於老齡化黃斑部病變(AMD)、糖尿病視網膜病變和視網膜靜脈阻塞 (RVO) 等視網膜疾病在全球範圍內流行，影響著全球超過 1.96 億人，視網膜藥物市場正在經歷顯著成長。人口老化、糖尿病患者數量增加以及眼科診斷和治療機會的改善等因素正在加速市場發展。市場主要由抗 VEGF 藥物主導，例如阿柏西普 (Eylea)、雷珠單抗 (Lucentis) 和溴珠單抗 (Beovu)，僅 Eylea 的全球銷售額就超過 90 億美元。此外，創新的緩釋性藥物傳遞系統和基因療法正在透過減少注射次數徹底改變治療方法，這對於患者的依從性至關重要。 Regenxbio、Roche 和 Kodiak Sciences 等主要企業憑藉先進的長效療法和玻璃體內植入引領這一領域。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Roche Holding AG（incl. Genentech）
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bayer AG
Allergan（AbbVie Inc.）
Alcon Inc.
Santen Pharmaceutical Co., Ltd.
MeiraGTx Holdings plc
Ocuphire Pharma, Inc.
Kodiak Sciences Inc.
Adverum Biotechnologies, Inc.
Oxurion NV
Graybug Vision, Inc.
Clearside Biomedical, Inc.
Outlook Therapeutics, Inc.
Iveric Bio（acquired by Astellas Pharma）
Sandoz（a Novartis spin-off for biosimilars）
Coherus BioSciences, Inc.
Biogen Inc.

結論和建議

簡介目錄

Product Code: SQMIG35I2364

Global Retinal Drugs Market size was valued at USD 20.20 Billion in 2023 and is poised to grow from USD 21.86 Billion in 2024 to USD 41.06 Billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The retinal drugs market is witnessing significant growth driven by the global prevalence of retinal diseases like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), affecting over 196 million people globally. Factors such as an aging population, rising diabetes cases, and enhanced access to ophthalmic diagnostics and treatments have amplified market development. Dominating the landscape are anti-VEGF drugs like aflibercept (Eylea), ranibizumab (Lucentis), and brolucizumab (Beovu), with Eylea alone generating over $9 billion in global sales. Additionally, innovative sustained-release drug delivery systems and gene therapy are revolutionizing treatment approaches by reducing injection frequency, which is critical for patient compliance. Key players like Regenxbio, Roche, and Kodiak Sciences are leading the charge with advanced longer-acting therapies and intravitreal implants.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Drugs Market Segments Analysis

The global Retinal Drugs market is segmented on the basis of Drug Classes, Indication, Formulation, Application, Distribution Channel and region. By Drug Classes, the market is segmented into Anti-VEGF Agents, Corticosteroids, Immunomodulators, Gene & Cell Therapies, Small Molecule Therapies, and Others. By Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. Based on Formulation, the market is segmented into Injectables, Implants, Eye Drops, Oral Tablets/Capsules, and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Retinal Drugs Market

The expansion of the global retinal drugs market can be attributed significantly to the rising prevalence of retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). In 2020, it was reported that over 196 million individuals were affected by AMD, a number projected to reach 288 million by 2040. Additionally, nearly 188 million people suffer from diabetic retinopathy and around 16.4 million from RVO. Contributing factors such as aging populations, increased screen time, and poor dietary habits are further escalating retinal health issues, enhancing the demand for effective therapeutic interventions. As patients gain access to earlier diagnoses and treatments, there is an increasing need for innovative therapies, including anti-VEGF medications, corticosteroids, and gene therapies to address these growing health concerns.

Restraints in the Global Retinal Drugs Market

Despite advancements in retinal treatment, the exorbitant cost of retinal drugs poses a substantial hurdle to market growth, particularly in low- and middle-income nations. Anti-VEGF medications, which are regarded as a cornerstone for treating various retinal conditions, are often priced prohibitively high. For example, Lucentis can range from $1,200 to $2,000 per injection, and patients might require these injections monthly. While biosimilars like Byooviz are available at lower prices, they still remain unaffordable for many healthcare systems and patients. Long-term treatment regimens further exacerbate the financial strain, as many public healthcare systems in developing regions lack the necessary funding to support these medications, while private insurance plans often exclude coverage for retinal diseases or impose substantial copayments that deter patient compliance.

Market Trends of the Global Retinal Drugs Market

The Global Retinal Drugs market is witnessing a significant trend towards the adoption of gene therapy as a groundbreaking solution for inherited retinal diseases, particularly for conditions that lack existing therapies. Leading pharmaceutical companies are investing in advanced candidates such as Regenxbio's RGX-314 and Adverum's ADVM-022, which utilize AAV-based vectors to facilitate sustained anti-VEGF expression. Additionally, MeiraGTx is making strides in developing therapies targeting rare retinal dystrophies. Despite being in clinical or early regulatory phases, these innovative therapies hold substantial strategic value, attributed to orphan drug designations, the potential for one-time treatments, and considerable pricing leverage, thereby establishing gene therapy as a key player in the future of retinal care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Value Chain Analysis
Regulatory Bodies
Pipeline Product Analysis
Case Studies

Global Retinal Drugs Market Size by Drug Classes & CAGR (2025-2032)

Market Overview
Anti-VEGF Agents
- VEGF-A Antagonists
- Dual-target Anti-angiogenic Agents
Corticosteroids
- Intravitreal Implants
- Injectable Suspensions
Immunomodulators
Gene & Cell Therapies
Small Molecule Therapies
Other Drug Classes

Global Retinal Drugs Market Size by Indication & CAGR (2025-2032)

Market Overview
Macular Degeneration
Diabetic Retinopathy
Uveitis
Others

Global Retinal Drugs Market Size by Formulation & CAGR (2025-2032)

Market Overview
Injectables (Solutions, Suspensions)
Implants (Biodegradable, Non-biodegradable)
Eye Drops
Oral Tablets/Capsules
Ointments & Gels

Global Retinal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Retinal Drugs Market Size & CAGR (2025-2032)

North America (Drug Classes, Indication, Formulation, Distribution Channel)
- US
- Canada
Europe (Drug Classes, Indication, Formulation, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Classes, Indication, Formulation, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Classes, Indication, Formulation, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Classes, Indication, Formulation, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Roche Holding AG (incl. Genentech)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (AbbVie Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MeiraGTx Holdings plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocuphire Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxurion NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Outlook Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iveric Bio (acquired by Astellas Pharma)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (a Novartis spin-off for biosimilars)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments